PRME Insider Trading

Insider Ownership Percentage: 23.47%
Insider Buying (Last 12 Months): $20,000,000.00
Insider Selling (Last 12 Months): $0.00

Prime Medicine Insider Trading History Chart

This chart shows the insider buying and selling history at Prime Medicine by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Prime Medicine Share Price & Price History

Current Price: $2.91
Price Change: Price Increase of +0.02 (0.69%)
As of 01/21/2025 05:00 PM ET

This chart shows the closing price history over time for PRME up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$2.91Closing price on 01/21/25:

SEC Filings (Institutional Ownership Changes) for Prime Medicine (NYSE:PRME)

70.37% of Prime Medicine stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PRME by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$378kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
Prime Medicine logo
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Read More on Prime Medicine

Today's Range

Now: $2.91
Low: $2.83
High: $3.03

50 Day Range

MA: $3.10
Low: $2.64
High: $4.32

52 Week Range

Now: $2.91
Low: $2.56
High: $9.77

Volume

767,027 shs

Average Volume

813,190 shs

Market Capitalization

$381.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Who are the company insiders with the largest holdings of Prime Medicine?

Prime Medicine's top insider shareholders include:
  1. Robert Nelsen (Director)
  2. 2019 Gp LLC Gv (Major Shareholder)
Learn More about top insider investors at Prime Medicine.

Who are the major institutional investors of Prime Medicine?

Prime Medicine's top institutional shareholders include:
  1. Green Alpha Advisors LLC — 0.05%
  2. SG Americas Securities LLC — 0.05%
  3. Avanza Fonder AB — 0.02%
  4. Impact Partnership Wealth LLC — 0.01%
  5. Nisa Investment Advisors LLC — 0.01%
Learn More about top institutional investors of Prime Medicine stock.

Which major investors are buying Prime Medicine stock?

Within the last quarter, PRME stock was purchased by institutional investors including:
  1. Green Alpha Advisors LLC
  2. Avanza Fonder AB
  3. Impact Partnership Wealth LLC
  4. SG Americas Securities LLC
  5. Nisa Investment Advisors LLC